Showing results (381-390 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 3, 2011
Eribulin mesylate in patients with refractory cancers: a Phase I studyToru Mukohara, Shunji Nagai, Hirofumi Mukai, et al.
Investigational New Drugs|May 1, 1990
Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinomaD L Trump, P Elson
Investigational New Drugs|October 15, 2011
ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activitiesFrankie Lam, Tracey D Bradshaw, Hui Mao, et al.
Investigational New Drugs|January 1, 1990
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot studyD L Trump, J C Marsh, L K Kvols, et al.
Investigational New Drugs|August 4, 2011
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumorsElisabeth I Heath, Karen Forman, Lisa Malburg, et al.
Investigational New Drugs|February 1, 1990
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomasR H Earhart, D J Amato, A Y Chang, et al.
Investigational New Drugs|February 1, 1990
Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivoW DeNeve, F Valeriote, E Tapazoglou, et al.
Investigational New Drugs|February 1, 1990
Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group studyC B Vaughn, S E Salmon, T R Fleming
Investigational New Drugs|September 9, 2011
A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagusKuai-le Zhao, Xi-chun Hu, Xiang-hua Wu, et al.
Investigational New Drugs|January 25, 2012
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study groupS H Park, M H Ryu, B Y Ryoo, et al.
Pageof 372